SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science receives approval for Rx, OTC Ranitidine tablets

25 Sep 2019 Evaluate

Strides Pharma Science has received an approval from US Food and Drug Administration (USFDA) for Rx and OTC Ranitidine tablets for the US market and is only commercializing the Rx product currently.

The USFDA has learned that some ranitidine products contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is also found in water and  foods,  including meats,  dairy  products,  and  vegetables  and  is  not  expected  to cause harm when ingested in very low levels. USFDA is not calling for individuals to stop taking ranitidine at this time. The agency is examining the levels of NDMA in ranitidine and is evaluating any possible risks to patients. Basis a Citizen petition, the USFDA is now reaching out to all formulation companies to perform tests to evaluate presence of NDMA in the product.

The company has also received an Information Request (IR) from USFDA to provide test data in next 30 days. The  company  is  in  the  process  of  responding  to  the  IR comprehensively. Further updates on the product will be provided post completion of the requisite tests.  Ranitidine tablets is amongst the top 5 products sold by the company in the USA.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×